Since dinaciclib and maritoclax have been shown to target MCL-1 synthesis and degradation respectively, we examined their efficacy in inducing apoptosis in three MCL-1-dependent NSCLC cell lines, H23, H460 and H1299 (Figs. 1D-1F). The gene discussed is MCL1; the disease is non-small cell lung carcinoma.